Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 735 matching trials from the live ClinicalTrials.gov search.
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
22
States / cities
Little Rock, Arkansas • Burbank, California • San Diego, California + 17 more
Conditions
Non Squamous Lung Cancer
Interventions
treatment
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
84
States / cities
Beverly Hills, California • Fontana, California • Loma Linda, California + 53 more
Conditions
Locally Advanced or Metastatic Malignant Solid Tumors
Interventions
enfortumab vedotin, pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
29
States / cities
Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy, carboplatin, paclitaxel, stereotactic body radiation therapy
Radiation · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Malignant Neoplasm
Interventions
MK-4700, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Hackensack, New Jersey • San Antonio, Texas
Conditions
Lung Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
Interventions
TTI-101
Drug
Lead sponsor
Tvardi Therapeutics, Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Conditions
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions
BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Clovis, California • Los Angeles, California • Newport Beach, California + 6 more
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Conditions
Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, NSCLC, Small Cell Lung Cancer, SCLC, Lung Cancer, Advanced Lung Cancer, Metastatic Lung Cancer, Stage IV Lung Cancer
Interventions
Lucitanib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Conditions
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
Interventions
PF-08046032, Sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Antonio, Texas • Seattle, Washington
Conditions
Lung Cancer
Interventions
carboplatin, erlotinib hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
124
States / cities
Little Rock, Arkansas • Antioch, California • Berkeley, California + 90 more
Conditions
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
Interventions
Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab
Drug · Biological
Lead sponsor
Intima Bioscience, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • Minneapolis, Minnesota
Conditions
Non Small Cell Lung Cancer
Interventions
Necitumumab, Gemcitabine, Cisplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
15
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Sacramento, California + 12 more
Conditions
Lung Cancer
Interventions
bevacizumab, vinorelbine tartrate
Biological · Drug
Lead sponsor
University of Rochester
Other
Eligibility
70 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Rochester, New York
Conditions
Lung Cancer
Interventions
ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis, Tc 99m sestamibi, radiation therapy
Drug · Other · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Azacitidine and Cisplatin
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Loma Linda, California
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
12
States / cities
Fort Myers, Florida • Augusta, Georgia • Gainesville, Georgia + 8 more
Conditions
Lung Cancer
Interventions
cetuximab, carboplatin, pemetrexed disodium, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
71
States / cities
Arroyo Grande, California • Castro Valley, California • Hayward, California + 56 more
Conditions
Lung Cancer
Interventions
docetaxel, gefitinib, laboratory biomarker analysis, radiation therapy
Drug · Other · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
Interventions
DM005
Drug
Lead sponsor
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Detroit, Michigan • Dallas, Texas • Fairfax, Virginia
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
Conditions
Non-Small Cell Lung Cancer, Melanoma
Interventions
LXH254, LTT462, Trametinib, Ribociclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Boston, Massachusetts + 3 more